SecurityRLJE / RLJ Entertainment, Inc. (74965F104)
CEOPENELLA MIGUEL
IndustryMotion Picture, Film, and Video Tape Distribution
Institutional Owners16
Institutional Shares1,206,077 - 7.97%
Common Shares Outstanding15,138,250 shares (as of 2018-03-31)
Institutional Value$ 5,386,000 USD
Related RLJEW / RLJ Entertainment, Inc.

Institutional Stock Ownership and Shareholders()

RLJE / RLJ Entertainment, Inc. Institutional Ownership

RLJ Entertainment, Inc. (NASDAQ:RLJE) has 16 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,206,077 shares. Largest shareholders include Teton Advisors, Inc., Gamco Investors, Inc. Et Al, Edge Wealth Management LLC, Gabelli Funds Llc, Geode Capital Management, Llc, Bridgeway Capital Management Inc, Bradley Foster & Sargent Inc/ct, Vanguard Group Inc, Renaissance Technologies LLC, and Deutsche Bank Ag\.
RLJ Entertainment, Inc. (NASDAQ:RLJE) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/rlje"><img src="https://images.fintel.io/us-rlje-so.png" alt="RLJE / RLJ Entertainment, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-04-05 13F-HR Edge Wealth Management LLC 168,400 168,400 0.00 606 753 24.26
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 72,900 58,600 -19.62 267 261 -2.25
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 91,642 91,642 0.00 335 408 21.79
2018-05-14 13F-HR Renaissance Technologies LLC 25,600 114
2018-05-09 13F-HR Teton Advisors, Inc. 401,000 405,000 1.00 1,475 1,810 22.71
2018-05-15 13F-HR DEUTSCHE BANK AG\ 5,717 20,960 266.63 21 93 342.86
2018-05-09 13F-HR GAMCO INVESTORS, INC. ET AL 176,128 187,228 6.30 648 837 29.17
2018-05-15 13F-HR VANGUARD GROUP INC 21,554 28,154 30.62 79 126 59.49
2018-05-07 13F-HR BRADLEY FOSTER & SARGENT INC/CT 56,300 56,300 0.00 206 252 22.33
2018-05-11 13F-HR Covington Capital Management 194 194 0.00 1 1 0.00
2018-05-15 13F-HR HIGHLAND CAPITAL MANAGEMENT LP 15,742 70
2018-05-15 13F-HR WOLVERINE ASSET MANAGEMENT LLC 2,400 2,400 0.00 8 10 25.00
2018-05-15 13F-HR UBS Group AG 3,000 1,889 -37.03 11 8 -27.27
2018-05-14 13F-HR MORGAN STANLEY 0 31 0 0
2018-05-14 13F-HR Virtu Financial LLC 18,881 84
2018-05-09 13F-HR GABELLI FUNDS LLC 80,026 125,056 56.27 294 559 90.14

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

RLJ Entertainment's (RLJE) CEO Miguel Penella on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good day ladies and gentlemen and welcome to the RLJ Entertainment First Quarter 2018 Earnings conference call. [Operator Instructions] As a reminder, this call may be recorded. (18-0)

Brightcove's (BCOV) CEO Jeff Ray on Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Greetings and welcome to the Brightcove First Quarter 2018 Earnings Call. At this time, all participants are in listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (12-0)

RLJ Entertainment's (RLJE) CEO Miguel Penella on Q4 2017 Results - Earnings Call Transcript

2018-03-15 seekingalpha
Good day, ladies and gentlemen and welcome to the Fourth Quarter 2017 RLJ Entertainment Inc. Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. (18-0)

CUSIP: 74965F104